Teva Pharmaceutical Reports Strong Q4 Earnings, Boosting Investor Confidence
Written by Emily J. Thompson, Senior Investment Analyst
Updated: Jan 28 2026
0mins
Should l Buy TEVA?
Source: Fool
Teva Pharmaceutical's stock surged 3.58% and reached a 52-week high following the announcement of its Q4 2025 earnings, which exceeded analyst expectations.
The company reported total revenue of $4.71 billion for Q4 2025, surpassing the anticipated $4.33 billion, and achieved an adjusted EPS of $0.96, exceeding expectations by $0.32. This strong performance, driven by key innovative products like Austedo, indicates a significant recovery and growth potential, despite a cautious outlook for 2026.
Teva's impressive earnings and revenue growth reflect its successful transition to a growth-driven business model, which may attract more long-term investors and enhance its competitiveness in the pharmaceutical industry.
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy TEVA?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
Analyst Views on TEVA
Wall Street analysts forecast TEVA stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for TEVA is 35.71 USD with a low forecast of 29.00 USD and a high forecast of 40.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.
11 Analyst Rating
10 Buy
1 Hold
0 Sell
Strong Buy
Current: 34.690
Low
29.00
Averages
35.71
High
40.00
Current: 34.690
Low
29.00
Averages
35.71
High
40.00
About TEVA
Teva Pharmaceutical Industries Ltd is a Israeli-based pharmaceutical company. The Company operates through three segments: North America, Europe and International Markets. Each business segment manages entire product portfolio in its region, including generics, specialty and over-the-counter (OTC) products. In addition to these three segments, The Company has other activities, primarily the sale of active pharmaceutical ingredients (API) to third parties, certain contract manufacturing services and an out-licensing platform offering a portfolio of products to other pharmaceutical companies through its affiliate Medis.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
Harel Insurance Sells KBWB ETF Shares Worth $330 Million
- Share Reduction: Harel Insurance disclosed on February 3, 2026, that it sold 4,177,000 shares of the Invesco KBW Bank ETF (KBWB), amounting to an estimated $330 million transaction, indicating a diminished confidence in this investment.
- Market Impact: The sale resulted in a $326.68 million decline in the value of its KBWB position, reflecting negative market movements and raising concerns about the future profitability of the banking sector amid changing interest rates.
- Strategic Shift: While reducing its KBWB holdings, Harel Insurance increased investments in healthcare (TEVA and XLV) and technology (GOOGL, NVMI, and SMH), suggesting a strategic pivot towards sectors expected to benefit from improving economic conditions and rising corporate spending on AI.
- ETF Performance Overview: As of February 2, 2026, KBWB was priced at $87.64, up 26.2% over the past year; however, in a declining interest rate environment, the potential for modest gains in bank ETFs like KBWB may necessitate cautious investor evaluation of future market performance.
See More
Harel Insurance Sells $330 Million in KBWB Shares
- Share Sale Scale: Harel Insurance disclosed in its SEC filing on February 3, 2026, that it sold 4,177,000 shares of the Invesco KBW Bank ETF (KBWB), with an estimated transaction value of approximately $330 million, reflecting its sensitivity to market dynamics.
- Asset Management Changes: This transaction resulted in a decline of $326.68 million in Harel's quarter-end position value, indicating a 2.9% negative impact on its assets under management (AUM), suggesting a need for reevaluation of its investment strategy.
- Portfolio Adjustment Strategy: Following the sale of KBWB shares, Harel holds only 620 shares valued at about $52,000, indicating a potential shift towards increasing investments in healthcare and technology sectors to navigate economic uncertainties.
- Market Environment Impact: With two rate cuts by the Federal Reserve, investors are cautious about the future performance of bank ETFs like KBWB, anticipating that lower interest rates will pressure banks' net interest margins and profits, potentially leading to slower growth in ETF returns.
See More
Stan Druckenmiller: The Influential Figure Behind Bessent and Warsh, Potential Candidates for Fed Chair
Trump's Federal Reserve Chair Pick: If Kevin Warsh is confirmed as Federal Reserve chair, it highlights his connection to influential financial leaders.
Stanley Druckenmiller's Influence: Investor Stanley Druckenmiller has mentored both Warsh and Treasury Secretary Scott Bessent, positioning him uniquely in Washington's financial landscape.
See More
Teva Pharmaceutical Stock Surges Nearly 400% Post-Leader Change
- Leadership Change: Teva Pharmaceutical appointed Richard Francis as its new leader at the beginning of 2023, resulting in a nearly 400% stock price increase from 2022 lows, indicating a significant recovery potential and boosting investor confidence.
- Annual Performance: Although Teva pre-announced quarterly results at the JPMorgan Healthcare conference, the actual results exceeded expectations; however, the full-year forecast was perceived as slightly light, leading to an initial 9% stock drop, reflecting market caution regarding future growth.
- Market Reaction: After the initial decline, Teva's stock stabilized and finished up more than 2% post-conference call, suggesting a gradual restoration of investor confidence and possibly indicating market recognition of its long-term value.
- Product Diversity: Teva not only produces generic drugs but also inhalers and treatments for migraines and cancer, while also engaging in contract manufacturing and supplying active pharmaceutical ingredients, showcasing its diversified positioning and competitiveness in the pharmaceutical industry.
See More
Deckers Stock Soars After Surprising Q3 Earnings Beat
- Earnings Surprise: Deckers reported a 7.1% revenue growth to $1.96 billion in its Q3 report, surpassing Wall Street's expectation of $1.87 billion, demonstrating the company's resilience in a challenging environment.
- Strong Brand Performance: HOKA sales surged by 18.5% to $628.9 million, while UGG also saw a solid 4.9% increase to $1.31 billion, indicating positive consumer response to new product offerings.
- Improved Profitability: Operating income rose by 8.3% to $614.4 million, achieving an operating margin of 31%, with earnings per share increasing by 11% to $3.33, significantly exceeding analyst expectations of $2.76, showcasing robust profitability.
- Optimistic Outlook: Management raised fiscal 2027 revenue guidance to $5.4 billion-$5.425 billion, projecting continued growth for HOKA and UGG, reflecting confidence in future market potential and strategic positioning.
See More
Novo Nordisk Accused of Victoza Monopoly Extension
- Antitrust Lawsuit: JM Smith Corporation's class action filed in the U.S. District Court alleges that Novo Nordisk unlawfully extended its monopoly over Victoza, preserving billions in profits while generating over $5 billion in U.S. sales in 2018 alone.
- Patent Expiration Impact: The last active pharmaceutical ingredient patent for Victoza expired in August 2022, and despite pediatric exclusivity extending until February 22, 2023, the plaintiffs argue that Novo's actions delayed generic entry, preventing patients from accessing lower-cost alternatives.
- Price Manipulation Allegations: The lawsuit claims that Novo Nordisk's unlawful reverse payment agreement with Teva delayed the launch of generic Victoza by at least 16 months, allowing both companies to charge supracompetitive prices, thereby increasing the financial burden on patients.
- Market Reaction: Novo Nordisk's stock fell by 0.87% to $58.82 at the time of publication, indicating market concerns regarding the antitrust allegations and their potential impact on the company's future profitability and market position.
See More
Harel Insurance Sells KBWB ETF Shares Worth $330 Million
- Share Reduction: Harel Insurance disclosed on February 3, 2026, that it sold 4,177,000 shares of the Invesco KBW Bank ETF (KBWB), amounting to an estimated $330 million transaction, indicating a diminished confidence in this investment.
- Market Impact: The sale resulted in a $326.68 million decline in the value of its KBWB position, reflecting negative market movements and raising concerns about the future profitability of the banking sector amid changing interest rates.
- Strategic Shift: While reducing its KBWB holdings, Harel Insurance increased investments in healthcare (TEVA and XLV) and technology (GOOGL, NVMI, and SMH), suggesting a strategic pivot towards sectors expected to benefit from improving economic conditions and rising corporate spending on AI.
- ETF Performance Overview: As of February 2, 2026, KBWB was priced at $87.64, up 26.2% over the past year; however, in a declining interest rate environment, the potential for modest gains in bank ETFs like KBWB may necessitate cautious investor evaluation of future market performance.
See More
Harel Insurance Sells $330 Million in KBWB Shares
- Share Sale Scale: Harel Insurance disclosed in its SEC filing on February 3, 2026, that it sold 4,177,000 shares of the Invesco KBW Bank ETF (KBWB), with an estimated transaction value of approximately $330 million, reflecting its sensitivity to market dynamics.
- Asset Management Changes: This transaction resulted in a decline of $326.68 million in Harel's quarter-end position value, indicating a 2.9% negative impact on its assets under management (AUM), suggesting a need for reevaluation of its investment strategy.
- Portfolio Adjustment Strategy: Following the sale of KBWB shares, Harel holds only 620 shares valued at about $52,000, indicating a potential shift towards increasing investments in healthcare and technology sectors to navigate economic uncertainties.
- Market Environment Impact: With two rate cuts by the Federal Reserve, investors are cautious about the future performance of bank ETFs like KBWB, anticipating that lower interest rates will pressure banks' net interest margins and profits, potentially leading to slower growth in ETF returns.
See More
Stan Druckenmiller: The Influential Figure Behind Bessent and Warsh, Potential Candidates for Fed Chair
Trump's Federal Reserve Chair Pick: If Kevin Warsh is confirmed as Federal Reserve chair, it highlights his connection to influential financial leaders.
Stanley Druckenmiller's Influence: Investor Stanley Druckenmiller has mentored both Warsh and Treasury Secretary Scott Bessent, positioning him uniquely in Washington's financial landscape.
See More
Teva Pharmaceutical Stock Surges Nearly 400% Post-Leader Change
- Leadership Change: Teva Pharmaceutical appointed Richard Francis as its new leader at the beginning of 2023, resulting in a nearly 400% stock price increase from 2022 lows, indicating a significant recovery potential and boosting investor confidence.
- Annual Performance: Although Teva pre-announced quarterly results at the JPMorgan Healthcare conference, the actual results exceeded expectations; however, the full-year forecast was perceived as slightly light, leading to an initial 9% stock drop, reflecting market caution regarding future growth.
- Market Reaction: After the initial decline, Teva's stock stabilized and finished up more than 2% post-conference call, suggesting a gradual restoration of investor confidence and possibly indicating market recognition of its long-term value.
- Product Diversity: Teva not only produces generic drugs but also inhalers and treatments for migraines and cancer, while also engaging in contract manufacturing and supplying active pharmaceutical ingredients, showcasing its diversified positioning and competitiveness in the pharmaceutical industry.
See More
Deckers Stock Soars After Surprising Q3 Earnings Beat
- Earnings Surprise: Deckers reported a 7.1% revenue growth to $1.96 billion in its Q3 report, surpassing Wall Street's expectation of $1.87 billion, demonstrating the company's resilience in a challenging environment.
- Strong Brand Performance: HOKA sales surged by 18.5% to $628.9 million, while UGG also saw a solid 4.9% increase to $1.31 billion, indicating positive consumer response to new product offerings.
- Improved Profitability: Operating income rose by 8.3% to $614.4 million, achieving an operating margin of 31%, with earnings per share increasing by 11% to $3.33, significantly exceeding analyst expectations of $2.76, showcasing robust profitability.
- Optimistic Outlook: Management raised fiscal 2027 revenue guidance to $5.4 billion-$5.425 billion, projecting continued growth for HOKA and UGG, reflecting confidence in future market potential and strategic positioning.
See More
Novo Nordisk Accused of Victoza Monopoly Extension
- Antitrust Lawsuit: JM Smith Corporation's class action filed in the U.S. District Court alleges that Novo Nordisk unlawfully extended its monopoly over Victoza, preserving billions in profits while generating over $5 billion in U.S. sales in 2018 alone.
- Patent Expiration Impact: The last active pharmaceutical ingredient patent for Victoza expired in August 2022, and despite pediatric exclusivity extending until February 22, 2023, the plaintiffs argue that Novo's actions delayed generic entry, preventing patients from accessing lower-cost alternatives.
- Price Manipulation Allegations: The lawsuit claims that Novo Nordisk's unlawful reverse payment agreement with Teva delayed the launch of generic Victoza by at least 16 months, allowing both companies to charge supracompetitive prices, thereby increasing the financial burden on patients.
- Market Reaction: Novo Nordisk's stock fell by 0.87% to $58.82 at the time of publication, indicating market concerns regarding the antitrust allegations and their potential impact on the company's future profitability and market position.
See More
